Historical Valuation
DENTSPLY SIRONA Inc (XRAY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.33 is considered Undervalued compared with the five-year average of 15.90. The fair price of DENTSPLY SIRONA Inc (XRAY) is between 32.43 to 47.19 according to relative valuation methord. Compared to the current price of 12.78 USD , DENTSPLY SIRONA Inc is Undervalued By 60.6%.
Relative Value
Fair Zone
32.43-47.19
Current Price：12.78
60.6%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
DENTSPLY SIRONA Inc (XRAY) has a current Price-to-Book (P/B) ratio of 1.52. Compared to its 3-year average P/B ratio of 1.83 , the current P/B ratio is approximately -16.77% higher. Relative to its 5-year average P/B ratio of 1.99, the current P/B ratio is about -23.57% higher. DENTSPLY SIRONA Inc (XRAY) has a Forward Free Cash Flow (FCF) yield of approximately 3.56%. Compared to its 3-year average FCF yield of 5.33%, the current FCF yield is approximately -33.30% lower. Relative to its 5-year average FCF yield of 5.34% , the current FCF yield is about -33.36% lower.
P/B
Median3y
1.83
Median5y
1.99
FCF Yield
Median3y
5.33
Median5y
5.34
Competitors Valuation Multiple
AI Analysis for XRAY
The average P/S ratio for XRAY competitors is 3.99, providing a benchmark for relative valuation. DENTSPLY SIRONA Inc Corp (XRAY.O) exhibits a P/S ratio of 0.61, which is -84.64% above the industry average. Given its robust revenue growth of -4.94%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for XRAY
1Y
3Y
5Y
Market capitalization of XRAY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XRAY in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is XRAY currently overvalued or undervalued?
DENTSPLY SIRONA Inc (XRAY) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.33 is considered Undervalued compared with the five-year average of 15.90. The fair price of DENTSPLY SIRONA Inc (XRAY) is between 32.43 to 47.19 according to relative valuation methord. Compared to the current price of 12.78 USD , DENTSPLY SIRONA Inc is Undervalued By 60.60% .
What is DENTSPLY SIRONA Inc (XRAY) fair value?
XRAY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of DENTSPLY SIRONA Inc (XRAY) is between 32.43 to 47.19 according to relative valuation methord.
How does XRAY's valuation metrics compare to the industry average?
The average P/S ratio for XRAY's competitors is 3.99, providing a benchmark for relative valuation. DENTSPLY SIRONA Inc Corp (XRAY) exhibits a P/S ratio of 0.61, which is -84.64% above the industry average. Given its robust revenue growth of -4.94%, this premium appears unsustainable.
What is the current P/B ratio for DENTSPLY SIRONA Inc (XRAY) as of Jan 10 2026?
As of Jan 10 2026, DENTSPLY SIRONA Inc (XRAY) has a P/B ratio of 1.52. This indicates that the market values XRAY at 1.52 times its book value.
What is the current FCF Yield for DENTSPLY SIRONA Inc (XRAY) as of Jan 10 2026?
As of Jan 10 2026, DENTSPLY SIRONA Inc (XRAY) has a FCF Yield of 3.56%. This means that for every dollar of DENTSPLY SIRONA Inc’s market capitalization, the company generates 3.56 cents in free cash flow.
What is the current Forward P/E ratio for DENTSPLY SIRONA Inc (XRAY) as of Jan 10 2026?
As of Jan 10 2026, DENTSPLY SIRONA Inc (XRAY) has a Forward P/E ratio of 7.33. This means the market is willing to pay $7.33 for every dollar of DENTSPLY SIRONA Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for DENTSPLY SIRONA Inc (XRAY) as of Jan 10 2026?
As of Jan 10 2026, DENTSPLY SIRONA Inc (XRAY) has a Forward P/S ratio of 0.61. This means the market is valuing XRAY at $0.61 for every dollar of expected revenue over the next 12 months.